APGE vs. VCEL, KYMR, TWST, RXRX, CGON, DNA, DNLI, BEAM, FUSN, and INBX
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Vericel (VCEL), Kymera Therapeutics (KYMR), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), CG Oncology (CGON), Ginkgo Bioworks (DNA), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Apogee Therapeutics (NASDAQ:APGE) and Vericel (NASDAQ:VCEL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.
In the previous week, Apogee Therapeutics had 13 more articles in the media than Vericel. MarketBeat recorded 24 mentions for Apogee Therapeutics and 11 mentions for Vericel. Apogee Therapeutics' average media sentiment score of 0.49 beat Vericel's score of 0.48 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Vericel has higher revenue and earnings than Apogee Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
79.0% of Apogee Therapeutics shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by company insiders. Comparatively, 5.2% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vericel received 320 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 62.22% of users gave Vericel an outperform vote.
Apogee Therapeutics currently has a consensus target price of $73.00, suggesting a potential upside of 45.10%. Vericel has a consensus target price of $46.80, suggesting a potential downside of 3.21%. Given Apogee Therapeutics' higher possible upside, equities analysts clearly believe Apogee Therapeutics is more favorable than Vericel.
Vericel has a net margin of 0.22% compared to Apogee Therapeutics' net margin of 0.00%. Vericel's return on equity of 0.21% beat Apogee Therapeutics' return on equity.
Summary
Apogee Therapeutics beats Vericel on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
